Targeting BCL ‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

(2020) Shaji K Kumar et al.   LANCET ONCOLOGY

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

(2019) Ujjawal H. Gandhi et al.   LEUKEMIA

Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

(2019) Philippe Moreau et al.   BLOOD

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

(2018) Brian A. Walker et al.   LEUKEMIA

Targeting Bcl-2 for the treatment of multiple myeloma

(2018) Cyrille Touzeau et al.   LEUKEMIA

Monoclonal antibody therapy in multiple myeloma

(2017) C Touzeau et al.   LEUKEMIA

High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma

(2017) A Miller et al.   Blood Cancer Journal

The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism

(2016) M. A. Anderson et al.   BLOOD

Treatment of relapsed and refractory multiple myeloma

(2016) Pieter Sonneveld et al.   HAEMATOLOGICA

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

(2016) Shaji Kumar et al.   LANCET ONCOLOGY

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

(2016) E. A. Punnoose et al.   MOLECULAR CANCER THERAPEUTICS

Treatment of relapsed and refractory multiple myeloma

(2016) Pieter Sonneveld et al.   HAEMATOLOGICA

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma

(2015) Brian A. Walker et al.   JOURNAL OF CLINICAL ONCOLOGY

BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics

(2015) C Touzeau et al.   LEUKEMIA

Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax

(2015) S M Matulis et al.   LEUKEMIA

Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma

(2015) Charlotte Kervoëlen et al.   Oncotarget

Patients with newly diagnosed multiple myeloma and chromosome 1 amplification have poor outcomes despite the use of novel triplet regimens

(2014) Noa Biran et al.   AMERICAN JOURNAL OF HEMATOLOGY

Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value

(2013) G. An et al.   HAEMATOLOGICA

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma

(2013) C Touzeau et al.   LEUKEMIA

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

(2011) S. V. Rajkumar et al.   BLOOD

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

(2011) S K Kumar et al.   LEUKEMIA

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols

(2010) Sarah Waheed et al.   CANCER